FDA Fundamental Analysis - FIDIA SPA

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to FDA. FDA was compared to 109 industry peers in the Machinery industry. FDA has a bad profitability rating. Also its financial health evaluation is rather negative. FDA has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year FDA has reported negative net income.

FDA had a positive operating cash flow in the past year.

FDA had negative earnings in 4 of the past 5 years.

In multiple years FDA reported negative operating cash flow during the last 5 years.

1.2 Ratios

FDA's Return On Assets of -8.49% is on the low side compared to the rest of the industry. FDA is outperformed by 84.40% of its industry peers.

FDA's Return On Equity of -53.14% is on the low side compared to the rest of the industry. FDA is outperformed by 87.16% of its industry peers.

		Industry Rank	Sector Rank
ROA	-8.49%
ROE	-53.14%
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

FDA's Gross Margin of 69.64% is amongst the best of the industry. FDA outperforms 94.50% of its industry peers.

In the last couple of years the Gross Margin of FDA has grown nicely.

The Profit Margin and Operating Margin are not available for FDA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	69.64%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y4.42%

GM growth 5Y4.76%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

FDA does not have a ROIC to compare to the WACC, probably because it is not profitable.

There is no outstanding debt for FDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

FDA has an Altman-Z score of 0.09. This is a bad value and indicates that FDA is not financially healthy and even has some risk of bankruptcy.

FDA has a Altman-Z score of 0.09. This is amonst the worse of the industry: FDA underperforms 80.73% of its industry peers.

FDA has a debt to FCF ratio of 6.13. This is a slightly negative value and a sign of low solvency as FDA would need 6.13 years to pay back of all of its debts.

FDA has a Debt to FCF ratio (6.13) which is comparable to the rest of the industry.

A Debt/Equity ratio of 1.41 is on the high side and indicates that FDA has dependencies on debt financing.

FDA's Debt to Equity ratio of 1.41 is on the low side compared to the rest of the industry. FDA is outperformed by 83.49% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.41
Debt/FCF	6.13
Altman-Z	0.09

ROIC/WACCN/A

WACC8.1%

2.3 Liquidity

A Current Ratio of 1.06 indicates that FDA should not have too much problems paying its short term obligations.

Looking at the Current ratio, with a value of 1.06, FDA is doing worse than 79.82% of the companies in the same industry.

FDA has a Quick Ratio of 1.06. This is a bad value and indicates that FDA is not financially healthy enough and could expect problems in meeting its short term obligations.

FDA has a Quick ratio of 0.46. This is amonst the worse of the industry: FDA underperforms 92.66% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.06
Quick Ratio	0.46

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

FDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.56%, which is quite impressive.

Looking at the last year, FDA shows a very negative growth in Revenue. The Revenue has decreased by -27.40% in the last year.

The Revenue for FDA have been decreasing by -17.51% on average. This is quite bad

EPS 1Y (TTM)70.56%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.95%

Revenue 1Y (TTM)-27.4%

Revenue growth 3Y-9.81%

Revenue growth 5Y-17.51%

Sales Q2Q%38.18%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FDA. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

97.25% of the companies in the same industry are more expensive than FDA, based on the Price/Free Cash Flow ratio.

		Industry Rank	Sector Rank
P/FCF	2.08
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for FDA!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

FIDIA SPA

BIT:FDA (1/8/2026, 1:15:25 PM)

0.122

+0 (+1.58%)

Chartmill FA Rating

GICS SectorIndustrials

GICS IndustryGroupCapital Goods

GICS IndustryMachinery

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners1.46%

Ins Owner ChangeN/A

Market Cap2.32M

Revenue(TTM)21.08M

Net Income(TTM)-2.19M

Analysts45.71

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.11
P/FCF	2.08
P/OCF	1.81
P/B	0.56
P/tB	0.65
EV/EBITDA	N/A

EPS(TTM)-6.13

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.06

FCFY48.11%

OCF(TTM)0.07

OCFY55.11%

SpS1.11

BVpS0.22

TBVpS0.19

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-8.49%
ROE	-53.14%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	69.64%
FCFM	5.28%

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y4.42%

GM growth 5Y4.76%

F-Score5

Asset Turnover0.82

Health

		Industry Rank	Sector Rank
Debt/Equity	1.41
Debt/FCF	6.13
Debt/EBITDA	N/A
Cap/Depr	12.72%
Cap/Sales	0.77%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.06
Quick Ratio	0.46
Altman-Z	0.09

F-Score5

WACC8.1%

ROIC/WACCN/A

Cap/Depr(3y)19.7%

Cap/Depr(5y)16.39%

Cap/Sales(3y)1.17%

Cap/Sales(5y)1.24%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)70.56%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.95%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-27.4%

Revenue growth 3Y-9.81%

Revenue growth 5Y-17.51%

Sales Q2Q%38.18%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-112.29%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-50.51%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-48.73%

OCF growth 3YN/A

OCF growth 5YN/A

FIDIA SPA / FDA.MI FAQ

What is the ChartMill fundamental rating of FIDIA SPA (FDA.MI) stock?

ChartMill assigns a fundamental rating of 1 / 10 to FDA.MI.

What is the valuation status for FDA stock?

ChartMill assigns a valuation rating of 2 / 10 to FIDIA SPA (FDA.MI). This can be considered as Overvalued.

How profitable is FIDIA SPA (FDA.MI) stock?

FIDIA SPA (FDA.MI) has a profitability rating of 2 / 10.

FIDIA SPA (FDA.MI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

FIDIA SPA / FDA.MI FAQ

What is the ChartMill fundamental rating of FIDIA SPA (FDA.MI) stock?

What is the valuation status for FDA stock?

How profitable is FIDIA SPA (FDA.MI) stock?